In the semi final session of the European Venture Contest, held on the 24th of October in Aarhus (Denmark), Laminar Pharma was one of the 6 projects selected by a prestigious panel of 21 directives of pharmaceutical companies and Venture Capital Funds specialized in healthcare investments.

The presentation made by Vicenç Tur, Laminar Pharma’s CEO, was focused on the applications of 2OHOA as a potential innovative drug for the treatment of malignant brain tumours (glioma)

Laminar Pharma presented yesterday 2OHOA as a new innovative drug for the potential treatment of glioma in the course of the semi final sessions of the European Venture Contest (ECV) Healthcare held in Aarhus (DK). 20 leading European biotech companies, previously selected among the most innovative and with the most promising prospects in the European biopharmaceutical market, presented their projects in front of a qualified panel of European & US VC investors and directives of pharmaceutical companies, including GlaxoSmithKline (GSK), Merck & Co (MSD), Novo Nordisk or DSM. Laminar Pharma’s project was one of the 6 awarded with the possibility of making a plenary presentation at the final session of the EVC Healthcare that will take place in Berlin next 6th and 7th of December as part of the European Venture Summit, where more that 100 VC investors and representatives of multinational pharmaceutical companies are expected. This award might have important consequences as it is probable that some of the projects presenting at this Berlin Summit will be able to get investments for their projects from some of the investors and pharmaceutical companies attending this important event.

The European Venture Contest is a prestigious European event organized by Europe Unlimited with the objective of finding, evaluating and awarding world-class innovative companies with the potential to dramatically impact their industry and contribute to increasing European competitiveness and growth. The Contest Jury, composed of 30 international investors with extensive experience in their respective fields will decide on the best 10 presenting companies (4 ICT, 3 life sciences and 3 cleantech) from more than 100 companies qualified through EVC 2012 Semi-Finals.